The Summary
In the phase 3, double-blind REIMAGINE 2 trial, researchers evaluated the efficacy of CagriSema—a once-weekly combination of the amylin receptor agonist cagrilintide and GLP-1 agonist semaglutide. The study randomized 2,713 adults with inadequately controlled type 2 diabetes and a BMI of 25 or higher across 30 countries. After 68 weeks, patients receiving high-dose CagriSema (2.4 mg of each drug) experienced a significantly greater reduction in HbA1c (-1.91%) compared to those taking high-dose semaglutide alone (-1.75%). Side effects were primarily gastrointestinal, aligning with established GLP-1 therapies.
Why this is interesting
While semaglutide is already a blockbuster treatment, some patients still struggle to reach their optimal blood sugar targets. CagriSema pairs semaglutide with cagrilintide, targeting two different appetite and metabolic pathways simultaneously. By proving superior to semaglutide alone, this combination drug represents the next frontier in metabolic health. For individuals with type 2 diabetes, this means a more powerful, dual-action option could soon be available to help master blood sugar control with a single weekly injection.